Molecular basis of the anti-cancer and anti-inflammation activities of JTE607
University Of California-Irvine, Irvine CA
Investigators
Linked publications, trials & patents
Abstract
Project Summary: The small molecule drug JTE-607 was discovered 20 years ago that inhibits the production of pro-inflammatory cytokines. Animal studies showed that JTE-607 can be used to treat multiple inflammation diseases, including septic shock, acute injury, and endotoxemia, and it has progressed through healthy human volunteer clinical studies. More recently it was discovered that this compound also displays anti-tumor activities. It is particularly potent against acute myeloid leukemia (AML) and Ewingâs sarcoma. Despite these promising pharmacological studies, the mechanism of action of JTE-607 remained unknown until recently. Two studies published recently revealed that JTE-607 is a prodrug that is converted to Compound 2 (Cmp2) in cells, which specifically binds to the CPSF73 protein, an essential mRNA 3â end processing factor. The 3â ends of almost all eukaryotic mRNAs are formed in two catalytic steps, an endonucleolytic cleavage and the addition of a string of adenosines (polyadenylation). CPSF73 is the endonuclease responsible for the cleavage step. It has been proposed that JTE-607 kills cancer cells by inducing mRNA 3â processing and transcription termination defects, which, in turn, cause genome instability and cell death. However, JTE-607 has not been directly tested in human mRNA 3â processing and it is unclear why JTE-607 only targets specific cancer types. We aim to identify the RNA sequences and the protein âsensorsâ that determine the drug sensitivity.These studies will reveal the in-depth mechanism of action of a novel anti-inflammation and anti-cancer compound. Characterization of the JTE-607-resistant mRNA 3â processing may identify novel target(s) for blocking mRNA 3â processing in future drug development. From the perspective of basic science, JTE-607 provides a unique tool for dissecting the mechanism of mRNA 3â processing and the discovery of multiple modes of mRNA 3â processing will have implications for our fundamental understanding of eukaryotic gene expression.
View original record on NIH RePORTER →